A citation-based method for searching scientific literature

Serhat Özçelik, Mehmet Çelik, Aşkı Vural, Bünyamin Aydın, Melike Özçelik, Hulya Gozu. Arch Med Sci 2020
Times Cited: 2







List of co-cited articles
3 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity








Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial.
Carol Wysham, Anuj Bhargava, Louis Chaykin, Raymond de la Rosa, Yehuda Handelsman, Lone N Troelsen, Kajsa Kvist, Paul Norwood. JAMA 2017
140
50


Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.
Alan J Garber, Allen B King, Stefano Del Prato, Seamus Sreenan, Mustafa K Balci, Manuel Muñoz-Torres, Julio Rosenstock, Lars A Endahl, Ann Marie Ocampo Francisco, Priscilla Hollander. Lancet 2012
236
50


More Similarities Than Differences Testing Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT Trial.
Julio Rosenstock, Alice Cheng, Robert Ritzel, Zsolt Bosnyak, Christine Devisme, Anna M G Cali, Jochen Sieber, Peter Stella, Xiangling Wang, Juan P Frías,[...]. Diabetes Care 2018
101
50

Glycaemic goal attainment and hypoglycaemia outcomes in type 2 diabetes patients initiating insulin glargine 300 units/mL or 100 units/mL: Real-world results from the DELIVER Naïve cohort study.
Timothy S Bailey, Fang L Zhou, Rishab A Gupta, Ronald Preblick, Vineet E Gupta, Paulos Berhanu, Lawrence Blonde. Diabetes Obes Metab 2019
16
50

New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2).
Hannele Yki-Järvinen, Richard Bergenstal, Monika Ziemen, Marek Wardecki, Isabel Muehlen-Bartmer, Emmanuelle Boelle, Matthew C Riddle. Diabetes Care 2014
181
50

Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial.
Leo Niskanen, Lawrence A Leiter, Edward Franek, Jianping Weng, Taner Damci, Manuel Muñoz-Torres, Jean-Paul Donnet, Lars Endahl, Trine Vang Skjøth, Allan Vaag. Eur J Endocrinol 2012
39
50




Practical Guidance on the Use of Premix Insulin Analogs in Initiating, Intensifying, or Switching Insulin Regimens in Type 2 Diabetes.
Ted Wu, Bryan Betty, Michelle Downie, Manish Khanolkar, Gary Kilov, Brandon Orr-Walker, Gordon Senator, Greg Fulcher. Diabetes Ther 2015
21
50

Role of premixed insulin analogues in the treatment of patients with type 2 diabetes mellitus: a narrative review.
Svetlana Elizarova, Gagik R Galstyan, Bruce H R Wolffenbuttel. J Diabetes 2014
10
50

Insulin Degludec, The New Generation Basal Insulin or Just another Basal Insulin?
Sami N Nasrallah, L Raymond Reynolds. Clin Med Insights Endocrinol Diabetes 2012
18
50

Twice-daily insulin glargine for patients with uncontrolled type 2 diabetes mellitus.
Mohsen Eledrisi, Noor Nabeel Suleiman, Obada Salameh, Mohammad Khair Hamad, Omar Rabadi, Ahmed Mohamed, Rana Al Adawi, Abdul Salam. J Clin Transl Endocrinol 2018
2
50


IDegAsp (insulin degludec + insulin aspart) for the management of type 2 diabetes: current status.
Jens Sandahl Christiansen, Philip Home, Ajay Kumar. Expert Rev Endocrinol Metab 2016
2
50

Switching to Once-Daily Insulin Degludec/Insulin Aspart from Basal Insulin Improves Postprandial Glycemia in Patients with Type 2 Diabetes Mellitus: Randomized Controlled Trial.
Kyu Yong Cho, Akinobu Nakamura, Chiho Oba-Yamamoto, Kazuhisa Tsuchida, Shingo Yanagiya, Naoki Manda, Yoshio Kurihara, Shin Aoki, Tatsuya Atsumi, Hideaki Miyoshi. Diabetes Metab J 2020
3
50



A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naive people with type 2 diabetes: a randomized, controlled trial.
Tim Heise, Cees J Tack, Robert Cuddihy, Jaime Davidson, Didier Gouet, Andreas Liebl, Enrique Romero, Henriette Mersebach, Patrik Dykiel, Rolf Jorde. Diabetes Care 2011
70
50


The Clinical Role of Insulin Degludec/Insulin Aspart in Type 2 Diabetes: An Empirical Perspective from Experience in Australia.
Sarah J Glastras, Neale Cohen, Thomas Dover, Gary Kilov, Richard J MacIsaac, Margaret McGill, Greg R Fulcher. J Clin Med 2020
2
50

Pragmatic use of insulin degludec/insulin aspart co-formulation: A multinational consensus statement.
Sanjay Kalra, Zafar A Latif, Abdurrahman Comlekci, Guillermo Gonzalez Galvez, Rached Malik, Md Faruque Pathan, Ajay Kumar. Indian J Endocrinol Metab 2016
7
50


Efficacy and safety of insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Chinese adults with type 2 diabetes: A phase III, open-label, 2:1 randomized, treat-to-target trial.
Wenying Yang, Jianhua Ma, Tianpei Hong, Ming Liu, Heng Miao, Yongde Peng, Changjiang Wang, Xiangjin Xu, Tao Yang, Anne M Nielsen,[...]. Diabetes Obes Metab 2019
7
50


(Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
Thomas Semlitsch, Jennifer Engler, Andrea Siebenhofer, Klaus Jeitler, Andrea Berghold, Karl Horvath. Cochrane Database Syst Rev 2020
11
50

Insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Asian patients with type 2 diabetes inadequately controlled on basal or pre-/self-mixed insulin: a 26-week, randomised, treat-to-target trial.
Shizuka Kaneko, Francis Chow, Dong Seop Choi, Shinji Taneda, Koichi Hirao, Yongsoo Park, Thomas Hasseriis Andersen, Mari-Anne Gall, Jens Sandahl Christiansen. Diabetes Res Clin Pract 2015
47
50

Efficacy and safety of switching from basal insulin to once-daily insulin degludec/insulin aspart in Japanese patients with inadequately controlled type 2 diabetes: A 4-week, randomized, open-label, treat-to-target study.
Yoshio Nagai, Ami Nishine, Eriko Hashimoto, Taiga Nakayama, Yosuke Sasaki, Mariko Murakami, Satoshi Ishii, Hiroyuki Kato, Yasushi Tanaka. J Diabetes Investig 2017
4
50

Comparison of Basal-Bolus and Premixed Insulin Regimens in Hospitalized Patients With Type 2 Diabetes.
Virginia Bellido, Lorena Suarez, Maria Galiana Rodriguez, Cecilia Sanchez, Marta Dieguez, Maria Riestra, Florentino Casal, Elias Delgado, Edelmiro Menendez, Guillermo E Umpierrez. Diabetes Care 2015
54
50


Favorable Glycemic Control with Once-Daily Insulin Degludec/Insulin Aspart after Changing from Basal Insulin in Adults with Type 2 Diabetes.
Han Na Jang, Ye Seul Yang, Seong Ok Lee, Tae Jung Oh, Bo Kyung Koo, Hye Seung Jung. Endocrinol Metab (Seoul) 2019
5
50


Insulin degludec/insulin aspart vs biphasic insulin aspart 30 twice daily in Japanese patients with type 2 diabetes: A randomized controlled trial.
Yukiko Onishi, Kenichi Yamada, Jeppe Zacho, Jan Ekelund, Yasuhiko Iwamoto. J Diabetes Investig 2017
5
50


Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec, in Children and Adolescents With Type 1 Diabetes: The onset 7 Trial.
Bruce W Bode, Violeta Iotova, Margarita Kovarenko, Lori M Laffel, Paturi V Rao, Srikanth Deenadayalan, Magnus Ekelund, Steffen Falgreen Larsen, Thomas Danne. Diabetes Care 2019
16
50

Comparison of insulin degludec/insulin aspart and biphasic insulin aspart 30 in uncontrolled, insulin-treated type 2 diabetes: a phase 3a, randomized, treat-to-target trial.
Gregory R Fulcher, Jens Sandahl Christiansen, Ganapathi Bantwal, Miroslawa Polaszewska-Muszynska, Henriette Mersebach, Thomas H Andersen, Leo K Niskanen. Diabetes Care 2014
68
50


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.